Oral deferiprone for iron chelation in people with thalassaemia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Fisher, Sheila A ^a   Brunskill, Susan J ^a   Doree, Carolyn ^a   Chowdhury, Onima ^b   Gooding, Sarah ^b   Roberts, David J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; PLACEBO; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRY WEIGHT; FERRITIN BLOOD LEVEL; GEOMETRY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; LIVER FIBROSIS; LIVER LEVEL; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; THALASSEMIA; URINARY EXCRETION; CHELATION THERAPY; IRON OVERLOAD; META ANALYSIS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CHELATION THERAPY; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALASSEMIA; TREATMENT OUTCOME;

EID: 84893487087     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004839.pub3     Document Type: Review

References (171)

1. Abdelrazik N. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience. Hematology 2007;12(6):577-85.
2. Abdelrazik N. Pattern of iron chelation therapy in Egyptian children with beta-thalassaemia: one-year Mansoura University Childrens Hospital experience [abstract]. Haematologica 2007;92 Suppl 1:Abstract 1146.
3. Aydinok Y, Evans P, Terzi A, Cetiner N, Porter JB. Randomised, prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO [abstract]. Blood 2005;106(11 Pt 1):2698.
4. Aydinok Y, El-Beshlawy A, von Orelli-Leber C, Czarnecki-Tarabishi C, Manz C. A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and Desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassaemia major [abstract]. Blood 2006;108(11):Abstract 557.
5. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, et al. A randomized, controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassaemia major. Haematologica 2007;92(12):1599-606.
6. Manz C, El-Beshlawy A, Aydinok Y, Leber C, Czarnecki-Tarabishi C. A randomized, controlled, prospective clinical study comparing the combination therapy of deferiprone (L1) and desferrioxamine (DFO) with L1 and DFO monotherapy in patients with thalassaemia major [abstract]. Haematologica 2006;91 Suppl 12:Abstract 515.
7. Choudhry VP, Pati HP, Saxena A, Malaviya AN. Deferiprone, efficacy and safety. Indian Journal of Pediatrics 2004;71(3):213-6.
8. El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, et al. Iron chelation in thalassaemia: combined or monotherapy? The Egyptian experience. Annals of Hematology 2008;87(7):545-50.
9. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al. A prospective randomised controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassaemia. Haematologica 2006;91(9):1241-3.
10. Galanello R, Kattamis A, Piga A, Tricta F. Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients [abstract]. Blood 2004;104(11 Pt 1):Abstract 3611.
11. Gomber S, Saxena R, Mada N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassaemic children. Indian Pediatrics 2004;41(1):21-7.
12. Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, et al. A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong. Hemoglobin 2006;30(2):263-74.
13. Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, et al. A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong. Hemoglobin 2006;30(2):263-74.
14. Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A, et al. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin 2003;27(2):63-76.
15. Maggio A, Capra M, Ciaccio C, Magnano C, Rizzo M, Mangiagili A, et al. Evaluatrion of efficacy of LI versus desferrioxamine by clinical randomised multicentric study [abstract]. Blood 1999;94(10 Suppl 1):34b.
16. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial. Blood Cells, Molecules and Diseases 2002;28(2):196-208.
17. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Decrease of mortality during deferiprone treatments: results from a large randomised cohort of thalassemia major patients under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies [abstract]. Blood 2008;112(11):Abstract 3885.
18. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells, Molecules and Diseases 2009;42(3):247-51.
19. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. British Journal of Haematology 2009;145(2):245-54.
20. Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients. Hemoglobin 2011;35(3):206-16.
21. Mourad FH, Hoffbrand, AV, Sheikah-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients. British Journal of Haematology 2003;121(1):187-9.
22. Olivieri NF, Kopren G, St Louis P, Freedman M, McClelland R, Templeton D. Studies of the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one in thalassaemia patients. Seminars in Haematology 1990;27(2):101-4.
23. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336(8726):1275-9.
24. Olivieri NF, Koren G, Hermann C, Chung D, McClelland R, Freedman M, et al. Effective iron chelation with L1 in patients with thalassemia major: iron balance and dose response studies [abstract]. Blood 1989;174(7 Suppl 1):51a.
25. Olivieri NF, Templeton DM, Koren G, Chung D, Herman C, Freedman MH, et al. Evaluation of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. Annals of the New York Academy of Sciences 1990;612:369-77.
26. ApoPharma Inc. US Food and Drug Administration. Oncologic drugs advisory committee briefing document: NDA #21-825. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm271469.htm Accessed 01 June 2013; Vol. Appendix A:100-1.
27. Hackman R, Berkovitch M, Sher G, Brittenham G, Koren G, Olivieri N. Studies of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in patients with beta-haemoglobinopathies: The Canadian trial [abstract]. Proceedings of the 25th Congress of the International Society of Hematology; 1994 April 17-21; Cancun. 1994:213.
28. Olivieri N and The Iron Chelation Research Group. Randomized trial of deferiprone (LI) and deferoxamine (DFO) in thalassemia major [abstract]. Blood 1996;10 Suppl 1:651a.
29. Olivieri NF, Brittenham GM. Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassaemia patients during treatment with deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood 1999;94(10 Suppl 1):35b.
30. Olivieri NF, Brittenham GM. Final results of the randomised trial of deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood 1997;90(10 Suppl 1):264a.
31. Olivieri NF, Brittenham GM. Armstrong SAM, Basran RK, Daneman R, Daneman N, et al. First prospective randomised trial of the iron chelators (L1) and deferoxamine [abstract]. Blood 1995;86(10 Suppl 1):249a.
32. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine 1994;331(9):574-8.
33. Pope E, Berkovitch M, Olivieri N, Koren G. First prospective randomized trial of subcutaneous deferoxamine and the orally active chelating agent L1. Proceedings of the 96th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1995 March 15-17; San Diego. 1995; Vol. World Meeting Number 951 0002.
34. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessops A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107(9):3738-44.
35. Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M, et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. Journal of Cardiovascular Magnetic Resonance 2011;13(1):34.
36. Tamaddoni A, Ramezani MS. Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients. Iranian Red Crescent Medical Journal 2010;12(6):655-9.
37. Alpendurada F, Carpenter JP, Smith GC, Tanner MA, Banya W, Galanello R, et al. Effect of myocardial iron removal on right ventricular function: insights from a randomized, placebo controlled, double blind trial in thalassemia major [abstract]. European Heart Journal 2010;31 Suppl 1:Abstract P451.
38. Tanner M. The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endomethial function in thalassaemia major: a randomised controlled trial using cardiovascular magnetic resonance [abstract]. Proceedings of the European Haematology Association 11th Congress. 2006:Abstract 0517.
39. Tanner MA, Galanello R, Dessi C, Agus A, Smith GC, Westwood MA, et al. Improved endothelial function with combined chelation therapy in thalassaemia major [abstract]. Blood 2006;108(11):Abstract 1770.
40. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 2007;115(14):1876-84.
41. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Khan M, et al. A randomized, placebo controlled double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance [abstract]. Blood 2005;106(11 Pt 1):Abstract 3655.
42. Agouzal M, Quyou A. Practice of iron chelation in the therapeutic center of thalassemia in Morocco [abstract]. Vox Sanguinis: 31st International Congress of the International Society of Blood Transfusion in Joint Cooperation with the 43rd Congress of the DGTI; Berlin, Germany. 2010:Abstract P-0879.
43. Al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. British Journal of Haematology 1992;82(2):431-6.
44. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360(9332):516-20.
45. Athanassiou MM, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi TF. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment (2). Acta Haematologica 2003;110(4):224-6.
46. Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, Tsatra I, Ikonomou M, Perifanis V, et al. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassaemia patients. Haematologica 2004;89(4):e55-e56.
47. Bartfay WJ, Lehotay DC, Sher GD, Bartfay E, Tyler B, Luo X, et al. Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassaemia patients chelated with deferoxamine or deferiprone (L1) versus no chelation. Haematology 1999;4(1):67-76.
48. Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, et al. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Annals of Hematology 2012;91(9):1443-9.
49. Christioforidis A, Zevgaridou E, Tsatra I, Perifanis V, Vlachaki E, Papassoitirou I, et al. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone. Journal of Paediatric Haematology and Oncology 2007;29(9):598-601.
50. Cohen A, Galanello R, Piga A, Vullo C. A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone. Annals of the New York Academy of Sciences 1998;850:223-6.
51. Diav-Citrin O, Atanackovic G, Loebstein R, Koren G. Investigation of variability in response to deferiprone (L1) inpatients with beta-thalassemia major [abstract]. Proceedings of the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5-8; San Diego. 1997.
52. Drakonaki EE, Maris TG, Maragaki S, Klironomos V, Papadakis A, Karantanas AH. Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study. Hemoglobin 2010;34(1):95-106.
53. Elalfy MS, Abdin I. Liver status in a cohort of polytransfused b-thalasseamie major (BTM) on long term desferrioxamine (DFO) or Deferiprone (L1) [abstract]. Blood 2006;108(11):Abstract 3732.
54. Fassos FF, Klein J, Fedrnandes D, Matsui D, Olivieri N, Koren G. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassaemia. Clinical Pharmacology and Therapeutics 1994;55(1):70-5.
55. Fragatou S, Politis C, Vandiadi K, Tsiapras D, Douskou M. Cardiac function in thalassaemics on combined deferoxamine and deferiprone therapy. Haematologica 2007;92:299, Abstract 0801.
56. Galanello R, Doneddu I, Dessi C, Defraia E, Dolci C, Leoni G, et al. Iron chelation in thalassemia major: Combined treatment with deferiprone (DFP) and desferrioxamine (DFO) [abstract]. Proceedings of the BIO IRON World Congress on Iron Metabolism; 2001 August 18-23; Cairns. 2001:P78.
57. Goulas V, Kourakli-Symeonidis A, Camoutisis C. Comparative effects of three iron chelation therapies on the quality of life in Greek patients with homozygous transfusion-dependent beta-thalassemia. http://www.hindawi.com/isrn/hematology/2012/139862/cta/(Accessed 01 August 2013).
58. Grady RW, Berdoukas V, Rachmilewitz EA, Galanello R, Borgna-Pignatti C, Ladis V. When deferiprone and desferrioxamine are combined iron excretion is enhanced [abstract]. Blood 2001;98(11 Pt 1):494a.
59. Grady RW, Berdoukas VA, Rachmilewitz EA, Galanello R, Borgna-Pignatti C, Ladis V, et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion [abstract]. Blood 2002;100:241a.
60. Grady RW, Hilgartner MW, Giardina PJ. Deferiprone: its efficacy relative to that of desferal [abstract]. Blood 1996;88(10):310a.
61. Hershko C, Hoffbrand A, Olivieri N, Al-Refaie F, Tondury P, Wonke B. International study group on oral iron chelators: Results of long-term deferiprone (LI) therapy [abstract]. Proceedings of the 2nd Meeting of the European Haematology Association; 1996 May 29-Jun 1; Paris. 1996:570.
62. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 2003;88(12):1423-5.
63. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. British Medical Journal 1987;295(6612):1509-12.
64. Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells, Molecules and Diseases 2010;45(2):136-9.
65. Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, et al. Immune function in patients with beta-thalassamia receiving the orally active iron-chelating agent deferiprone. British Journal of Haematology 1997;98(3):597-600.
66. Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, et al. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study. Mutagenesis 2003;18(5):457-63.
67. Nielsen P, Fischer R, Engelhardt R, Tondury P, Gabbe EE, Janka GE. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. British Journal of Haematology 1995;91(4):827-33.
68. Olivieri N, Brittenham G, Koren G. Reduction in hepatic iron stores with the oral iron chelator L1 inpatients with transfusion-dependent thalassemia and sickle cell disease: First three years of the Canadian trial [abstract]. Proceedings of the 35th Annual Meeting and Exposition of the American Society of Hematology; 1993 December 3-7; St. Louis. 1993:1238.
69. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. European Journal of Haematology 2003;70(6):392-7.
70. Peng CT, Wu KH, Tsai CC, Ysai CH. Deferirpone in patients with beta-thalassamiea major for 4 years in the Chinese population in Taiwan. European Journal of Clinical Investigation 2004 Suppl 1;34:20-61; Abstract 138.
71. Peng CT, Wu KH, Tsai CH, Yang CP, Wang LW, Jang RC, et al. Study of deferiprone or deferoxamine versus combination therapy in iron-loaded thalassaemia patients in Taiwan. Blood 2006;18 Suppl:Abstract 3736.
72. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassaemia major by multislice multiecho T2*. European Journal of Haematology 2006;76(3):183-92.
73. Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, et al. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. European Journal of Haematology 2010;85(1):36-42.
74. St Pierre TG. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003;361(9352):182.
75. Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Comparison between deferoxamine and deferiprone (L1) in iron-loaded patients. European Journal of Haematology 2001;67(1):30-4.
76. Tanner MA, Galanello R, Dessi C, Smirth GC, Westwood MA, Agus A, et al. Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Journal of Cardiovascular Magnetic Resonance 2008;10(1):12-20.
77. Tsakok AD. Deferiprone versus deferoxamine in patients with thalassaemia major: a randomized clinical trial. Blood Cells, Molecules and Diseases 2004;32(1):139-40.
78. Vlachaki E, Ioannidou-Papagiannaki E, Haralambidou-Vranitsa SH, Perifanis V, Tsigga A, Klonizakis I, et al. Progenitor haemopoietic cells in the peripheral blood of thalassemic patients with desferioxamine or deferiprone chelation therapy [abstract]. Hematology 2005;90 Suppl 2:Abstract 1065.
79. Vlachaki E, Ioannidou-Papagiannaki E, Tziomalos K, Haralambidou-Vranitsa S, Perifanis V, Klonizakis I, et al. Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. European Journal of Haematology 2007;78(1):48-51.
80. Wang CH, Wu KH, T FJ, Peng CT, T CH. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassaemia major patients. Hemoglobin 2006;30(2):257-62.
81. Zareifar S, Jabbari A, Cohan N, Haghpanah S. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia. Archives of Iranian Medicine 2009;12(5):488-91.
82. Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, et al. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassemia major. Journal of Cardiovascular Magnetic Resonance 2012;14(1):8. [DOI:]
83. Aydinok Y, Evans P, Manz CY, Porter JB. Probing the origin of chelatable iron during deferiprone and combination therapies: insights from plasma NTBI and LPI determinations. ASH Annual Meeting Abstracts 2010;116(21):5158.
84. Aydinok Y, Evans P, Manz CY, Porter JB. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Haematologica 2012;97(6):835-41.
85. Badawy S, Hassan TH, Hesham MAA, Badr MA. Evaluation of iron chelation therapy in beta-thalassemic patients in Zagazig University Hospital. Pediatric Blood and Cancer; Proceedings of the 23rd Annual Meeting of the American Society of Pediatric Hematology/Oncology, ASPHO, Montreal, Canada. 2010:799-800, Poster 124.
86. Hassan T, Badr M, Hesham M, Badawy S. Evaluation of iron chelation therapy in beta-thalassemia major patients in East Delta of Egypt. Haematologica. 2010 Suppl 2; Vol. 95:701, Abstract 1810.
87. Evans P, Aydinok Y, Manz C, Porter J. Origin of chelatable iron during deferiprone and combination therapies: Insights from plasma NTBI and LPI. American Journal of Hematology. 2011; Vol. 86:9: E84.
88. Jain R, Perkins J, Johnson S, Harimoorthy V, Desai P, Chudgar U, et al. A prospective study for determination of the mean red cell transfusion requirement compared on the basis of iron overload and type of chelation therapy in multiply transfused thalassaemia major patients. Transfusion Medicine 2011;21(1):46-7.
89. Kompany F, Mohammadi S, Sigari N, Hadizadeh N, Rezaie N, Gharibi FSM. Comparative efficacy of deferrioxamine and combination of deferiprone and deferrioxamine on echocardiographic indices in beta thalassemic patients. Scientific Journal of Kurdistan University of Medical Sciences 2009;14(2):21-30.
90. Maggio A, Capra M, Cuccia L, Gagliardotto F, Rigano P, Calvaruso G, et al. Long-term use of deferiprone enhances significantly the left ventricular ejection function in thalassemia major. ASH Annual Meeting Abstracts; 53rd American Society of Hematology (ASH) Annual Meeting, 10-13 December 2011, San Diego, USA 2011;118:21; Abstract 5302.
91. Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F, et al. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalssemia major patients. American Journal of Hematology 2012;87(7):732-3.
92. Mirbehbahani N, Jahazi A, Rahim AHH. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients. Hematology 2012;17(3):183-6.
93. Wonke B. A randomised controlled prospective trial using Ferriprox versus placebo and conventional intravenous and subcutaneous iron chelation. National Research register: N0277104959.
94. National Heart, Lung and Blood Institute (NHLBI). Combination therapy compared with single-drug therapy in patients with cardiac diseases. ClinicalTrials.gov: NCT00115349.
95. Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients. Hemoglobin 2011;35(3):206-16.
96. Pepe A, Meloni A, Pepe P, Capra M, D'Ascola DG, Santodirocco M, et al. Prospective comparison on cardiac and hepatic iron and cardiac function by MR in thalssemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy. Blood 2011;118(21):Abstract.
97. Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. http://www.jcmr-online.com/content/pdf/1532-429X-15-1.pdf (Accessed 01 August 2013). [DOI:]
98. Pepe A, Meloni A, Rossi G, Ruffo GB, D'Ascola DG, Santodirocco M, et al. Cardiac iron and function by CMR in thalassemia major patients treated with combined deferiprone and desferrioxamine regimen versus monotherapies: a multi-center, observational and prospective study. European Heart Journal 2012;33:805.
99. Pepe A, Rossi G, Meloni A, Dell'Amico MC, Capra M, Caruso V, et al. Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy. ASH Annual Meeting Abstracts 2010;116(21):5164.
100. Pepe A, Rossi G, Meloni A, Dell'Amico MC, Capra M, Caruso V, et al. Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy. Haematologica, Proceedings of the 15th Congress of the European Hematology Association, Barcelona, Spain 2010 Suppl 2;95:696 Abstract 1797.
101. Unal S, Hazirolan T, Beton B, Karabulut E, Gumruk F. The cardiac effects of desferrioxamine deferiprone combination therapy and desferrioxamine monotherapy in thalassemic patients. Haematologica 2009 Suppl 2;94:514-5, Abstract 1295.
102. Fondazione Franco e Piera Cutino (Sponsors). Sequential deferasirox-deferiprone versus deferasirox or deferiprone multicentre randomized trial. EU Clinical Trials Register: 2009-014666-25 2010.
103. Akramipoor R. The comparative study of incidence of lens opacity between Osfereal and Deferoxamine in major thalassemia. Iranian Registry of Clinical Trials: IRCT20110087677N1.
104. Mohsen Saleh Elalfy, Ain Shams University. Study of efficacy, safety of combined deferasirox and deferiprone versus combined deferiprone and desferal in conditions of iron overload. ClinicalTrials.gov: NCT01511848.
105. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health and Quality of Life Outcomes 2006;4:73.
106. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, et al. Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion-dependent thalassaemia: Indian trial. British Journal of Haematology 1992;82(2):460-6.
107. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica 1990;84(3):113-7.
108. Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, et al. Practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93(5):741-52.
109. Bacon BR, Tavil AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. Journal of Clinical Investigation 1983;71(3):429-39.
110. Berdoukas V, Bohane T, Eagle C, Lindeman R, DeSilva K, Tobias V, et al. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). Transfusion Science 2000;23(3):239-40.
111. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Annals of the New York Academy of Sciences 1998;850:227-31.
112. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89(10):1187-93.
113. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine 1994;331(9):567-73.
114. Brittenham GM, Nathan DG, Olivieri NF, Porter JB, Pippard M, Vichinsky EP, et al. Deferiprone and hepatic fibrosis. Blood 2003;101(12):5089-90.
115. Caro JJ, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review. http://www.biomedcentral.com/1471-2326/2/4 2002 (accessed 21 May 2007); Vol. 2, issue 4.
116. Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology 2002;118(1):330-6.
117. Cohen AR, Galanello R, Piga A, DeSanctis V, Tricta F. Safety and effectiveness of long term therapy with the oral iron chelator deferiprone profile of the oral iron chelator: a multicentre study. Blood 2003;102(5):1583-7.
118. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;23(2):181-4.
119. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
120. Del Vecchio GC, Crollo E, Schettini F, Fischer R, De Mattia D. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematologica 2000;104(2-3):99-102.
121. Ehlers KH, Giardina PJ, Leser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with desferrioxamine. Journal of Paediatrics 1991;118(4 Pt 1):540-5.
122. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
123. Evangeli M, Mughal K, Porter JB. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Hemoglobin 2010;34(3):305-21.
124. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with thalassaemia major: applicability of SQUID biomagnetic liver susceptometry. British Journal of Haematology 2003;121(6):938-48.
125. Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI:]
126. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica 1996;95(1):26-36.
127. Gallant T, Freedman MH, Vellend H, Francombe WH. Yersinia sepsis in patients with iron overload treated with deferoxamine. New England Journal of Medicine 1986;314(25):1643.
128. Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007;109(12):5157-9.
129. Hider RC, Kontoghiorghes G, Silver J, Stockham MA. Pharmaceutically active hydroxypyridones. GB patent 21-46989 1984.
130. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
131. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
132. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Wiley - Blackwell, 2011.
133. Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91(1):295-300.
134. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, et al. Long term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-1 (L1), I: iron chelation and metabolic studies. British Journal of Haematology 1990;76(2):295-300.
135. Kontzoglou G, Koussi A, Tsatra J, Noussios G, Vital V, Sagarakis G, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece. International Journal of Pediatric Otorhinolaryngology 1996;35(3):223-30.
136. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2001;1:47-61.
137. Lucas GN, Perera BJ, Fonseka EA, Silva DD, Fernandopulle M, Karunatilaka DH, et al. Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon Medical Journal 2002;47(4):119-21.
138. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. British Journal of Haematology 2007;138(4):407-21.
139. Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules and Diseases 2011;47(3):166-75.
140. Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: systematic review and meta-analysis. British Journal of Haematology 2008;141(6):882-90.
141. Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA, et al. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica 1998;83(6):496-501.
142. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355(9220):2051-2.
143. Nathan DG, Weatherall DJ. Academic freedom in clinical research. New England Journal of Medicine 2002;347(17):1368-71.
144. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107(9):3436-41.
145. Olivieri NF, Buncic R, Chew E, Gallant T, Harrison RV, Keenan N, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New England Journal of Medicine 1986;314(14):869-73.
146. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79(10):2741-8.
147. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine 1994;331(9):574-8.
148. Olivieri NF, Brittenham GM, Armstrong SAM, Barsran RK, Daneman R, Daneman N, et al. First prospective randomized trial of the iron chelators deferiprone and deferoxamine [abstract]. Blood 1995;86 Suppl 1:249a.
149. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. New England Journal of Medicine 1995;332(14):918-22.
150. Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood 1997;90 Suppl 1:264a.
151. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89(3):739-61.
152. Olivieri N, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine 1998;339(7):417-23.
153. Olivieri NF. The beta-thalassemias. New England Journal of Medicine 1999;341(2):99-109.
154. Pati HP, Choudry VP. Deferiprone (L1) associated neutropenia in beta thalassaemia major: an Indian experience. European Journal of Haematology 1999;63(4):267-8.
155. Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High dose desferrioxamine as a cause of growth failure in thalassaemic patients. European Journal of Haematology 1988;40(4):380-1.
156. Pippard MJ, Letsky EA, Callender ST, Weatherall DJ. Prevention of iron loading in transfusion-dependent thalassaemia. Lancet 1978;1(8075):1178-81.
157. Porter J, Huehns E. The toxic effects of desferrioxamine. Balliere's Clinical Haematology 1989;2(2):459-74.
158. Porter JB, Jawson MS, Huehns ER, East CA, Hazell JWP. Desferrioxamine ototoxicity: evaluation of risk factors in thalassamic patients and guidelines for safe dosage. British Journal of Haematology 1989;73(3):403-9.
159. Porter J, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Practice Research in Clinical Haematology 2002;15(2):329-68.
160. Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. New England Journal of Medicine 1976;294(26):1421-3.
161. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. New England Journal of Medicine 1977;297(8):418-23.
162. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
163. Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt E, et al. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. Australian and New Zealand Journal of Medicine 1993;23(6):656-61.
164. Rombos Y, Tzanetea R, Konstantopoulos K, Simitizis S, Zervas C, Kyriaki P, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000;85(2):115-7.
165. Swedish Orphan Drug International AB. Ferriprox (Deferiprone) Summary of Product Charcteristics. www. Swedishorphan.com (accessed 2007).
166. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, et al. L1 (1, 2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. British Journal of Haematology 1990;76(4):550-3.
167. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. British Journal of Haematology 1998;101(3):413-5.
168. Viens AM, Savulescu J. Introduction to the Olivieri symposium. Journal of Medical Ethics 2004;30(1):1-7.
169. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100(5):1566-9.
170. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th Edition. Oxford: Blackwell Science, 2002.
171. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. New England Journal of Medicine 1985;312(25):1600-3.